Coastem Kemon announced on the 26th that it has submitted an application for approval of a Phase 1/2a clinical trial plan to evaluate the safety and efficacy of combined treatment with allogeneic bone marrow-derived mesenchymal stem cells and immunosuppressants in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
